I attended the Synairgen AGM earlier this week (Tuesday June 14th) which was held at the offices of Fladgate LLP, 16 Great Queen Street, London. For anyone who is unfamiliar with the company, Synairgen are an AIM listed UK based biotech focused on developing new treatments for Asthma, COPD and other respiratory diseases. Their current market cap is around £26M. Synairgen currently have one compound undergoing a confirmatory Phase II clinical study in asthma (funded entirely by Astra Zeneca) and a second compound in preclinical development for the treatment of Idiopathic Pulmonary Fibrosis (a rare lung disease with an orphan disease designation). They currently have cash reserves of around £6M (estimated). Link to Synairgen Website: http://www.synairgen.com/about-us/ Link to recent Investor meeting report (April 2016): http://uk.advfn.com/cmn/fbb/thread.php3?id=9359794&from=331#fir... There were only
...Not a member? Join today
Joining ShareSoc helps to empower our collective voice in representing investors, but we also offer exclusive benefits:
Member events & Masterclasses
Regular newsletter
Member only on-line Forums / Q&As
Company data and Voting Guidance
Educational resources
Get involved in our activities
Already a member?
Log in to your account to access this content and all of your other ShareSoc membership benefits.